1 / 20

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma. Presented By Antoni Ribas at 2014 ASCO Annual Meeting. Disclosures. Presented By Antoni Ribas at 2014 ASCO Annual Meeting.

aderes
Download Presentation

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  3. Pembrolizumab and Available Clinical Data: KEYNOTE-001 (NCT01295827) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  4. 411 Patients in Melanoma Expansion Cohorts: KEYNOTE-001 Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  5. KEYNOTE-001 Eligibility Criteria Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  6. KEYNOTE-001 Eligibility Criteria Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  7. Baseline Characteristics (1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  8. Baseline Characteristics (2) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  9. Summary of Exposurea and <br />Treatment-Related AEs by Prior IPI Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  10. Treatment-Related AEs With Incidence >5% Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  11. Immune-Mediated AEs Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  12. Maximum Percent Change from Baseline in Tumor Sizea (Central Review, RECIST v1.1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  13. Maximum Percent Change from Baseline in Tumor Sizea (Central Review, irRC) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  14. Confirmed ORR in Subgroups (Central Review, RECIST v1.1) Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  15. Antitumor Activity by Prior Ipilimumab and Pembrolizumab Dose/Schedule Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  16. Slide 16 Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  17. Kaplan-Meier Estimate of PFS per RECIST 1.1, Independent Central Review Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  18. Kaplan-Meier Estimate of Overall Survival Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  19. Summary Presented By Antoni Ribas at 2014 ASCO Annual Meeting

  20. Acknowledgments Presented By Antoni Ribas at 2014 ASCO Annual Meeting

More Related